Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to ...
Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1 ...
BRANDON, FL, UNITED STATES, November 3, 2024 /EINPresswire / -- Learning to Achieve Wellness has carved out a unique space in the world of mental < ...
Election season is in full swing, but as anyone can tell you, campaigns begin to enter their full speed much earlier in the ...
Stephens analyst Mason Carrico notes that Myriad Genetics (MYGN) shares are down about 20% this morning, which the firm ...
UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) ...
Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...